Project Grant K99CA300889
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$167K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $645,323 to The Washington University to investigate mechanisms of acid signaling in bone metastases of breast cancer. The goal is to understand how acid and cytokine production in the tumor microenvironment induces an immune-suppressive phenotype in myeloid cells, leading to resistance to immune checkpoint blockade therapy. The researchers will use genetic and pharmacological...
The National Cancer Institute (NCI) awarded a $321,213 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Rockefeller University. The grant supports research focused on understanding how colorectal cancer cells dynamically alter their metabolism and organellar interactions, particularly between the endoplasmic reticulum and mitochondria, in response to the tumor microenvironment. The project aims to identify the molecular mechanisms by which hypoxia inhibits these...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $293,369 to Duke University to conduct research on mechanisms of macrophage-mediated immune evasion in residual tumors. The research aims to uncover potential strategies to target and engineer the immune-mediated clearance of residual tumor cells that can lead to cancer relapse, even after initial response to oncogene-targeted therapies. The award period runs from Aug 1, 2024 to Mar 31,...
This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
The National Cancer Institute (NCI) awarded a $107,948 Project Grant to The Johns Hopkins University to conduct research on comparative analysis of M-CSF and GM-CSF in human monocyte metabolic reprogramming and differentiation into tumor-associated macrophage-like cells. The project, funded under CFDA 93.398 Cancer Research Manpower, aims to characterize differences in tumor-associated macrophage (TAM) functional attributes and their regulation between M-CSF and GM-CSF, as well as investigate...
This $107,948.00 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program to Weill Medical College of Cornell University, a private non-profit academic medical institution. The grant supports research to dissect the functional consequences of mutations in the ZFP36L2 gene and its impact on tumor progression and the immune microenvironment in colorectal cancer. The key objectives are to: 1) Delineate how ZFP36L2 regulates the...
This $174,767 Project Grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research into host defense mechanisms of resident peritoneal macrophages. Specifically, the awardee, Washington University, will examine how large peritoneal macrophages interact with mesothelial surfaces and promote clotting in the peritoneal cavity. This appears aimed at better understanding the immune response against infections and tumors in the peritoneum. The...
The federal Project Grant award K99CA297011, totaling $154,642.00, was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) to the Sloan-Kettering Institute for Cancer Research. The grant supports research aimed at elucidating the evolving immunopeptidome of metastatic colorectal cancer (mCRC) and identifying conserved intracellular targets for therapeutic interventions. Specifically, the research will systematically analyze the immunopeptidome of normal colon,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug treatment for inhibiting cancer growth and metastasis, particularly for ovarian, lung, and colon cancers. The research aims to leverage tumor-associated hyperactive membrane-anchored serine proteases on the surface of malignant tumor cells to selectively deliver potent cytotoxins and enhance sensitivity...
The National Cancer Institute (NCI) awarded a $113,372 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Washington University, a prominent private research institution in Missouri. The grant, effective March 1, 2025 through February 28, 2027, will support research to uncover the molecular mechanisms and understand the role of SERPINE family genes underlying rhabdoid tumorigenesis. The research aims to identify the molecular signatures and mechanisms driving...